NCT04585893View on ClinicalTrials.gov

Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

August 30, 2024

Study Completion Date

June 7, 2026

Conditions
Multicentric Castleman Disease
Interventions
DRUG

Rituximab

375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.

DRUG

Etoposide

Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab

Trial Locations (1)

Unknown

UNC Project, Kamuzu Central Hospital, Lilongwe

All Listed Sponsors
collaborator

Fogarty International Center of the National Institute of Health

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER